Coal India: The board of directors of Coal India has approved revision of Non-Coking coal prices with effect from 31st May 2023. The board has approved price increase of 8% over the existing notified prices for high grade coal of grade G2 to G10. Due to this revision, Coal India will earn approx. incremental revenue of Rs 2703 crore for the balance period of financial year 2023-24.

Adani Ports and Special Economic Zone (APSEZ): The company reported consolidated net profit of Rs 1,140.99 crore in Q4 FY23 as against a net profit of Rs 1,111.63 crore in Q4 FY22. Total income rose to Rs 6,179.12 crore in the quarter ended 31 March 2023 from Rs 4,739.08 crore recorded in Q4 FY22.

Torrent Pharmaceuticals: The company reported consolidated net profit of Rs 287 crore in Q4 FY23 as against a net loss of Rs 118 crore in Q4 FY22. Total income rose to Rs 2500 crore in the quarter ended 31 March 2023 from Rs 2187 crore recorded in Q4 FY22.

Mankind Pharma: The company's consolidated net profit rose 52% to Rs 294 crore in Q4 FY23 as against a net profit of Rs 193 crore in Q4 FY22. Revenue from operations rose 19% to Rs 2053 crore in the quarter ended 31 March 2023 from Rs 1726 crore recorded in Q4 FY22.

HDFC Life Insurance Company: UK-based investment company Abrdn is reportedly likely to sell its entire 1.66% equity in HDFC Life Insurance Company via block deals.

Lupin: The pharma major announced a strategic collaboration with Enzene Biosciences to launch Cetuximab in India, the first biosimilar developed for Cetuximab.

Powered by Capital Market - Live News